The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INVA | -12.34% | +71.77% | +11.43% | +27% |
| S&P | +15.06% | +95.03% | +14.29% | +494% |
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
These stocks are just temporarily inconvenienced large caps in the making.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $103.74M | 0.4% |
| Gross Profit | $83.11M | -2.2% |
| Gross Margin | 80.12% | -2.1% |
| Market Cap | $1.26B | 23.1% |
| Market Cap / Employee | $9.93M | 0.0% |
| Employees | 127 | 13.4% |
| Net Income | $63.69M | 283.6% |
| EBITDA | $58.79M | -9.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $397.53M | 83.2% |
| Accounts Receivable | $88.26M | -6.1% |
| Inventory | 49 | 33.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $317.04M | -29.4% |
| Short Term Debt | $200.28M | 13703.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.02% | -9.4% |
| Return On Invested Capital | 4.24% | -4.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $44.07M | 0.8% |
| Operating Free Cash Flow | $44.07M | 0.8% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 9.92 | 28.08 | 82.93 | 60.55 | 784.91% |
| Price to Book | 1.81 | 1.62 | 1.64 | 1.95 | 33.20% |
| Price to Sales | 3.32 | 3.92 | 2.96 | 4.42 | 48.34% |
| Price to Tangible Book Value | 2.75 | 2.47 | 2.44 | 2.95 | 32.44% |
| Price to Free Cash Flow TTM | 7.49 | 7.75 | 5.68 | 8.47 | 30.14% |
| Enterprise Value to EBITDA | 26.41 | 28.22 | 22.21 | 29.19 | 49.79% |
| Free Cash Flow Yield | 13.4% | 12.9% | 17.6% | 11.8% | -23.16% |
| Return on Equity | 10.0% | 3.4% | -8.8% | 5.6% | -76.50% |
| Total Debt | $450.91M | $451.10M | $451.26M | $517.32M | 14.78% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
